Neuro News Roundup: Potential MS Therapies

September 30, 2016
Mark L. Fuerst

Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Amiselimod, a second generation spin-off of fingolimod, may be a new potential treatment in MS and potentially other immune-mediated inflammatory diseases. Alemtuzumab may be a useful addition to the armamentarium as first-line treatment for relapsing-remitting MS (RRMS). Arbaclofen extended-release tablets may be more effective at decreasing spasticity related to MS than the commonly used spasticity-fighting drug baclofen.